About Cell Therapeutics, Inc.Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/. Sign up for email alerts and get RSS feeds at CTI's Web site, http://www.CellTherapeutics.com/investors_alert About Brown University Oncology Research Group (BrUOG) The Brown University Oncology Research Group (BrUOG) was created in 1994 to coordinate clinical cancer research for Brown's affiliated hospitals and Warren Alpert Medical School faculty. Since that time more than 3,000 Rhode Islanders have been treated on BrUOG trials at area hospitals. BrUOG's main mission is to improve cancer care through the implementation of innovative, multidisciplinary cancer clinical trials. Before BrUOG was founded, there was no unifying body for such research through which Brown's myriad scientists and physicians could share their ideas on the treatment of cancer. The trials sponsored by BrUOG investigate novel, cutting-edge applications of chemotherapeutic agents, biologic agents, and other cancer treatments. Today besides the 5 Rhode Island main member hospitals, Rhode Island Hospital, The Miriam Hospital, Women and Infants Hospital, Roger Williams Hospital and Memorial Hospital, BrUOG studies are also implemented in 8 other states nationwide. This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of OPAXIO include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with OPAXIO in particular, including, without limitation, the potential failure of OPAXIO to prove safe and effective and/or less toxic and effective for the treatment of newly diagnosed high-grade malignant brain tumors such as GBM, including when combined with TMZ and RT, the potential failure of OPAXIO when combined with TMZ and RT to provide PFS and OS responses to newly-diagnosed high-grade malignant brain tumors such as GBM, that the results of the new OPAXIO study may not be positive or be used to plan a phase III study of OPAXIO for approval for use in treating newly diagnosed GBM, that CTI cannot predict or guarantee the pace of patient enrollment in the phase II clinical study comparing OPAXIO to TMZ, UW's and CTI's ability to continue to raise capital as needed to fund this study and its operations, competitive factors, technological developments, costs of developing, producing and selling CTI's product candidates such as OPAXIO, and the risk factors listed or described from time to time in CTI's filings with the U.S. Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise. Clinical Trial Enrollment Contact: Sandra K. Johnston, PhD, RNT: 206.616.7117E: firstname.lastname@example.org Media Contact: Dan EramianT: 206.272.4343C: 206.854.1200E: email@example.com www.CellTherapeutics.com/press_room Investors Contact: Ed BellT: 206.282.7100 Lindsey Jesch LoganT: 206.272.4347F: 206.272.4434E: firstname.lastname@example.org www.CellTherapeutics.com/investors Medical Information Contact: T: 800.715.0944E: email@example.com SOURCE Cell Therapeutics, Inc.